Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub
https://doi.org/10.64483/202522393

Insulin Pump Therapy in Nursing Practice: Patient Education, Glycemic Monitoring, and Clinical Safety

Sultan Falah Sultan Al-Qahtani (1) , Zahrah Hussein Shabani (2) , Mada Mohammad Al-Otaibj (1) , Zahra Mesfer Summan Al Fayi (1) , Shaykhah Rasheed Binmozan (3) , Manal Ghazi Alharthi (3) , Khulud Abdullah Aldosseri (1) , Areej Mahboub Al Samti (1) , Badr Talal Boydr Alanizi (4)

(1) Badr 3 Primary Health Care Center, Ministry of Health, Saudi Arabia,
(2) Badr 3 Health Center, Ministry of Health, Saudi Arabia,
(3) Cluster 1, Riyadh – Badr 3, Ministry of Health, Saudi Arabia,
(4) Ministry of Education – Prince University, Saudi Arabia

Abstract

Background: Diabetes mellitus affects over 500 million people globally, with type 1 diabetes requiring lifelong insulin therapy. Insulin pump therapy, or continuous subcutaneous insulin infusion (CSII), has evolved as a cornerstone for intensive insulin management, offering improved glycemic control and flexibility compared to multiple daily injections.

Aim: To explore the clinical significance, operational principles, and nursing interventions associated with insulin pump therapy, emphasizing patient education and safety.

Methods: A comprehensive review of historical developments, device components, insulin delivery mechanisms, and evidence-based nursing practices was conducted, integrating clinical trials and guidelines to outline best practices for inpatient and outpatient care.

Results: CSII improves glycemic control, reduces hypoglycemia risk, and enhances patient satisfaction. Advanced features such as bolus calculators, auto-mode algorithms, and predictive low-glucose suspend systems further optimize outcomes. However, therapy introduces risks including infusion-site complications, rapid-onset hyperglycemia, and diabetic ketoacidosis during delivery interruptions. Nursing interventions—such as structured education, infusion-site monitoring, and contingency planning—are critical for safety.

Conclusion: Insulin pump therapy represents a clinically significant advancement in diabetes care, requiring interprofessional collaboration and vigilant nursing oversight to maximize benefits and minimize risks.

Keywords: Insulin pump therapy, continuous subcutaneous insulin infusion, glycemic control, nursing education, diabetes management, patient safety

Introduction

The global burden of diabetes mellitus has expanded at an unprecedented rate, with epidemiologic trends indicating a fourfold increase in prevalence over the last three to four decades. Contemporary estimates suggest that diabetes now affects more than 500 million individuals worldwide, and approximately 90% of these cases are attributable to type 2 diabetes mellitus.[1][2] Although type 2 diabetes can often be managed with lifestyle modification and oral antihyperglycemic agents, a substantial proportion of patients ultimately require insulin therapy to achieve durable glycemic control, prevent microvascular and macrovascular complications, and address progressive β-cell dysfunction that evolves over time. In contrast, type 1 diabetes mellitus is characterized by absolute insulin deficiency and remains intrinsically insulin-dependent from diagnosis, frequently affecting children and adolescents younger than 18 years of age. The early onset and lifelong nature of insulin dependence in this population introduce unique clinical, developmental, and psychosocial challenges, including variable insulin sensitivity during growth, the unpredictability of physical activity and dietary intake, and the heightened vulnerability to both acute dysglycemic emergencies and long-term complications.[1][2] Against this clinical background, the history of insulin therapy represents one of the most consequential narratives in modern

*Corresponding author e-mail: sufaalqahtani@gmail.com (Sultan Falah Sultan Al-Qahtani).

Receive Date: 30 November 2025, Revise Date: 25 December 2025, Accept Date: 27 December 2025

medicine, transforming type 1 diabetes from a rapidly fatal illness into a manageable chronic condition. In the early twentieth century, the first patient with type 1 diabetes was successfully treated with insulin, an intervention that effectively served as a lifesaving breakthrough at a time when therapeutic options were otherwise negligible.[3] Subsequent decades witnessed continuing scientific refinement in insulin production and purification, culminating by the end of the twentieth century in the development of human insulin. This transition helped reduce immunogenicity associated with earlier animal-derived formulations and expanded the capacity for standardized manufacturing and dosing precision. In parallel, pharmacologic innovation yielded an increasingly diverse range of insulin preparations tailored to physiologic requirements and clinical circumstances. Currently available options include short-acting and ultra–short-acting formulations designed for prandial coverage, intermediate-acting insulins intended to provide basal support, and long-acting and ultra–long-acting preparations that better approximate endogenous basal insulin secretion. Mixed preparations, combining basal and bolus components in fixed ratios, were also developed to simplify regimens in selected populations.[3] The creation of insulin analogs through genetic engineering further advanced therapy by producing molecules structurally similar to human insulin yet modified to achieve more predictable absorption, distribution, and duration of action, thereby improving both glycemic stability and regimen flexibility.[3]

Alongside pharmacologic progress, the evolution of insulin delivery systems has been equally influential in shaping diabetes management. For many years, injections using syringes were the dominant method of administration, but their limitations included dosing imprecision, logistical burden, and challenges with adherence. The introduction of insulin pens represented a notable improvement, enhancing both convenience and accuracy and reducing barriers to self-administration for many patients. Pens also supported more consistent technique and facilitated integration of insulin therapy into daily life, which is particularly important for individuals who require multiple daily injections. These delivery advances contributed meaningfully to improved patient engagement and, in turn, to better glycemic outcomes in routine clinical care. A pivotal innovation emerged in the late twentieth century with the development of continuous subcutaneous insulin infusion (CSII), now commonly referred to as insulin pump therapy. The earliest insulin pumps were strikingly rudimentary by modern standards; the first devices were approximately the size of an Army backpack. Initial concepts included "closed-loop" systems designed to deliver insulin—and, in some versions, dextrose—based on a computerized algorithm that responded to real-time glucose measurement. In these prototypes, the glucose analyzer was integrated within the device, and insulin dosing was computed dynamically. While scientifically ambitious, these systems were constrained by their physical size, operational complexity, and limited practicality, resulting in use largely confined to research environments. Subsequent iterations employed "open-loop" approaches, delivering insulin intravenously at a preset basal rate with boluses delivered at substantially higher rates, reported as up to 15 times the baseline delivery. However, this intravenous strategy introduced complications such as recurrent infections and phlebitis, which further restricted clinical adoption and underscored the need for safer, more sustainable infusion routes. In 1976, the first commercially available insulin pump was introduced and became known colloquially as the "blue brick," later termed the Auto Syringe. This device was designed by Kamen and represented an important milestone in translating pump technology from experimental settings into clinical application. Nevertheless, early commercial pump therapy was accompanied by significant adverse events, including hyperglycemia, diabetic ketoacidosis, and local infection at the infusion site. These complications were amplified by limitations in early hardware reliability, insulin stability, infusion set performance, and user training, leading to cautious uptake and relatively limited acceptance until the 1990s, when improvements in device engineering and clinical protocols became more widespread. The historical pattern is instructive: each technological leap in insulin delivery was accompanied by a parallel need for patient education, clinical monitoring standards, and systems-based safeguards to ensure that increased therapeutic capability translated into real-world safety.

In recent decades, refined engineering, improved infusion materials, enhanced user interfaces, and better integration with glucose monitoring have collectively transformed insulin pumps into far more practical, safer, and clinically effective tools. These newer technologies have improved dosing accuracy, supported flexible basal programming, facilitated bolus calculations, and reduced user burden, thereby contributing to improved glycemic control and quality of life for many insulin-dependent patients. As pump therapy has become more common, it has increasingly been viewed as a mainstay for individuals who require intensive insulin regimens, including many with type 1 diabetes and selected patients with insulin-requiring type 2 diabetes. However, contemporary adoption has also highlighted inequities in access. Recent studies have described disparities in insulin pump utilization across populations, even in settings where medical insurance plans cover device costs.[4] Such disparities suggest that barriers extend beyond financing and may include differences in referral patterns, patient education, health literacy, technology availability, and systemic inequities that influence who receives advanced diabetes therapies. From a definitional standpoint, insulin pumps are electronic or mechanical devices that deliver rapid-acting (short-acting or ultra–short-acting) insulin continuously through subcutaneous infusion. The device provides a basal infusion rate—either predetermined by programmed settings or automatically adjusted in more advanced systems—and allows for user-initiated bolus dosing to cover meals or correct hyperglycemia. This continuous delivery strategy aims to approximate physiologic insulin secretion more closely than intermittent injections by providing steady background insulin with the capacity for rapid dose modulation in response to dietary intake, activity, stress, or illness. In clinical terms, pump therapy is best understood not merely as a device but as a therapeutic platform that requires patient competency, clinician oversight, and ongoing education to ensure safety and effectiveness. It introduces opportunities for superior glycemic precision but also creates vulnerabilities if insulin delivery is interrupted, infusion sites fail, or user errors occur, making structured training and monitoring essential components of comprehensive pump-based diabetes management.[1][2][4]

Insulin Pump Parts

Insulin pump therapy is often described as a “device-based” approach to insulin administration, yet its clinical function depends on an interrelated set of components that work together to deliver insulin safely, continuously, and predictably.



Fig. 1: Insulin Pump.

From a nursing perspective, understanding the parts of an insulin pump is not merely technical knowledge; it directly supports patient education, troubleshooting of hyperglycemia or unexplained hypoglycemia, prevention of infusion-site complications, and early identification of device failures that can precipitate diabetic ketoacidosis, particularly in individuals with type 1 diabetes who have no endogenous insulin reserve. Although insulin pump brands vary in design, most systems can be understood through three core elements: the pump unit itself, the infusion set that connects the pump to the patient, and—when applicable—continuous glucose monitoring (CGM) components, including a sensor and transmitter in sensor-augmented pumps. The pump unit is the central controller and delivery engine of the system. It houses the insulin reservoir, the power source, and the electronics that regulate basal insulin infusion and patient-initiated bolus dosing. In conventional “tethered” pumps, the unit is worn externally and connects to the infusion set via thin plastic tubing. This tubing acts as the conduit through which insulin moves from the reservoir, through the pump mechanism, and into the subcutaneous cannula. Some newer systems minimize or eliminate the tubing by integrating the reservoir and delivery mechanism into a single wearable unit; these are commonly termed tubeless pumps. Despite differences in form factor, the fundamental role of the pump remains constant: it delivers rapid-acting insulin in small, precisely metered increments across the day and provides user interfaces for dose adjustment, history review, alarms, and maintenance functions [3][4].

The reservoir within the pump is a replaceable cartridge or chamber that stores insulin for ongoing delivery. It is typically changed every two to three days, a schedule driven by practical insulin volume limitations and by clinical considerations related to infusion-site reliability and infection prevention. Reservoir capacity usually corresponds to a two- to three-day supply of rapid-acting insulin analog, although the actual duration depends on a patient's total daily dose requirements. Patients with higher insulin needs may require more frequent reservoir changes, whereas those with lower requirements may approach the maximum wear time. Reservoir replacement is also required once the insulin is depleted, regardless of how many days have elapsed, because continued delivery requires an uninterrupted insulin supply. From a nursing education standpoint, it is important that patients understand that an "empty reservoir" is not a minor inconvenience; it is an immediate risk factor for hyperglycemia and, in susceptible patients, for rapid progression to ketosis if insulin delivery is not restored promptly. Power is another essential component of the pump unit. Battery designs vary across devices: some use rechargeable lithium batteries that are replenished via a cable, while others rely on standard alkaline batteries. The practical implication is that insulin pump function is inseparable from reliable power availability. Pumps should remain on whenever a functional battery is present, because discontinuing pump operation effectively interrupts basal insulin delivery. Many devices employ standby or low-power modes to conserve energy; however, even when a pump is conserving battery, the clinical priority remains to ensure that basal delivery continues as prescribed. Nurses play a key role in reinforcing that low-battery alerts should never be ignored and that patients should maintain a plan for battery replacement or charging, particularly during travel, illness, or other disruptions to routine [3][4].

Equally important is the user interface, which translates pump capability into daily diabetes self-management. Most pumps provide a home screen that displays current status and offers navigation to basal settings, bolus history, active insulin calculations, alarms, and configuration menus. Reviewing basal profiles is clinically relevant because basal rates may vary across the day to match circadian changes in insulin sensitivity. Bolus history, in turn, provides insight into meal coverage patterns and correction dosing, which can inform education and clinical adjustments. Pumps also include priming functions, which are essential when changing infusion sets or reservoirs to remove air, ensure insulin is present within the tubing, and confirm that delivery pathways are patent. Returning to an active home screen or completing a priming sequence often requires device-specific button presses or touchscreen steps, which vary by manufacturer. This variability underscores why patient training must be individualized and reinforced with hands-on demonstration rather than generic instructions. From a clinical safety perspective, difficulty navigating the pump interface can translate into delayed troubleshooting, missed boluses, or improper priming, each of which can affect glycemic stability. The infusion set is the component that physically connects the pump to the patient's body and serves as the final pathway for insulin delivery into subcutaneous tissue. In most tethered systems, the infusion set consists of tubing, connectors, and a small cannula that sits in the subcutaneous space. The cannula may be inserted manually or through an insertion device, and it is secured to the skin with adhesive. The infusion set must maintain a stable position and an unobstructed lumen to deliver consistent insulin flow; therefore, site selection, insertion technique, and routine replacement are central to pump safety. Infusion sets are commonly placed in areas with adequate subcutaneous tissue such as the abdomen, upper arm, upper thigh, or lower back. Rotating sites is crucial to reduce local irritation, prevent lipohypertrophy, and preserve reliable absorption. The adhesive component is not trivial: poor adhesion can lead to partial dislodgement, leakage, or complete cannula removal, and patients who sweat heavily or have sensitive skin may require additional strategies to maintain secure placement. From a nursing standpoint, the infusion set is often the "weak link" when unexplained hyperglycemia occurs. Kinking of the cannula, occlusion of the tubing, leakage at the connector, or inflammatory changes at the insertion site can all interrupt insulin delivery even when the pump appears functional. Because insulin pumps typically use rapid-acting insulin only, any interruption in basal infusion can lead to a rapid rise in blood glucose and, in high-risk patients, ketosis within hours. This is why education emphasizes recognizing early warning signs, responding to occlusion alarms, assessing the insertion site for redness, pain, or dampness, and changing the infusion set promptly when delivery failure is suspected [3][4].

In sensor-augmented insulin pump systems, an additional set of components supports glucose monitoring and, in some designs, automated insulin adjustment. These include a subcutaneous glucose sensor and a transmitter that communicates glucose readings to the pump. The sensor detects interstitial glucose trends, and the transmitter relays data to the pump interface for display and, when enabled, for algorithm-driven features such as automated basal modulation. While the pump's primary role remains insulin delivery, the integration of sensor input can enhance safety by providing trend information, hypoglycemia alerts, and data that support more precise therapy adjustments. These features, however, require proper sensor placement, calibration or initialization steps depending on device, and patient understanding of how sensor readings differ from capillary blood glucose values, especially during rapid glucose changes. The type of insulin used in pumps is itself an essential "component" of pump therapy, because pump delivery assumptions are built around the pharmacokinetics of rapid-acting formulations. Most commonly, rapid-acting insulin analogs such as lispro, aspart, or glulisine are used, though other rapid-acting insulins may also be employed depending on clinical context and device compatibility.[5] These insulins provide timely onset for bolus dosing and predictable action profiles suitable for continuous infusion. In selected patients with poorly controlled diabetes who require very high total daily doses—often described as exceeding 100 units per day—U-500 concentrated regular insulin may be used in the pump. This approach can reduce how frequently the reservoir must be replaced by increasing the amount of insulin delivered per unit volume.[6] However, the use of concentrated insulin also demands heightened clinical oversight and patient education, because dosing calculations, pump programming, and error consequences differ from standard U-100 insulin use. For nursing practice, this means ensuring that patients understand the specific concentration in their pump, that prescriptions and education materials align with that concentration, and that transitions of care include explicit documentation to prevent potentially dangerous misunderstandings. In summary, insulin pump systems comprise more than a single device: they involve a pump unit with reservoir and power supply, an infusion set that maintains subcutaneous access, and, in many contemporary configurations, sensor and transmitter components that support continuous glucose data integration. Each part carries both functional importance and distinct failure modes. For nurses, mastery of these components supports proactive patient teaching, safer pump handling during hospitalization or outpatient care, and rapid identification of problems that could otherwise escalate into severe dysglycemia [3][4][5].

Insulin Delivery

Insulin pump therapy operationalizes a physiologic concept—continuous basal insulin replacement with flexible prandial and corrective dosing—through a programmable platform that can be individualized to a patient's metabolic needs, lifestyle patterns, and risk profile for hypoglycemia. In nursing practice, understanding insulin delivery via pumps is essential because safe outcomes rely not only on the device's technical capability but also on the patient's competence in carbohydrate estimation, response to alarms, and interpretation of glucose trends. Pumps can improve glycemic stability by providing small, frequent microdoses of rapid-acting insulin and by offering decision-support tools such as bolus calculators and automated basal modulation. However, because pump therapy typically uses rapid-acting insulin alone, interruption of delivery can lead to abrupt hyperglycemia and, in susceptible patients, diabetic ketoacidosis. Therefore, insulin delivery principles must be taught clearly, reinforced repeatedly, and monitored across transitions of care. The foundational component of insulin pump delivery is basal insulin. Basal delivery refers to the continuous infusion of insulin across the full 24-hour period to suppress hepatic glucose production and maintain near-euglycemia between meals and overnight. In pump therapy, basal insulin is delivered either at a preset rate determined by the clinician and user, or at an auto-adjusted rate in systems capable of algorithmic modulation. Basal rates are commonly programmed in segments to reflect diurnal variation in insulin sensitivity, such as increased basal requirements in the early morning due to counterregulatory hormone surges. From a clinical standpoint, basal dosing is the backbone of glycemic control: if basal delivery is too low, fasting hyperglycemia and ketogenesis risk increase; if too high, recurrent hypoglycemia—often nocturnal—becomes more likely. Nurses caring for pump users should be attentive to patterns that suggest basal mismatch, including persistent fasting hyperglycemia, early-morning hypoglycemia, or repeated lows unrelated to meal boluses. In both outpatient education and inpatient safety planning, emphasizing that basal delivery must continue without interruption is critical, because pump suspension, depleted reservoirs, or infusion-set occlusion can rapidly compromise metabolic stability [5][6][7].

Prandial insulin in pump therapy is delivered as a mealtime bolus. The bolus is intended to match the glycemic load of carbohydrate intake and is typically calculated based on the amount of carbohydrates the patient expects to consume. Most pump systems support a bolus calculator that integrates a user-specific insulin-to-carbohydrate ratio (ICR). The ICR represents the number of grams of carbohydrate covered by one unit of insulin and must be programmed into the pump in advance, either by the clinician or through structured self-management guidance. A commonly cited estimate for calculating ICR is the formula ICR = 450/TDD, where TDD refers to the total daily dose of insulin.[7] Although this calculation offers a starting point, clinical refinement is usually required because insulin sensitivity varies with age, weight, activity level, hormonal status, and concurrent illness. From a nursing perspective, the ICR is an educational cornerstone: patients must understand that inaccurate carbohydrate counting or misapplication of the ICR can cause significant postprandial excursions. Practical teaching often includes strategies for portion estimation, reading nutrition labels, accounting for mixed meals, and recognizing circumstances in which bolus timing or dose may need adjustment, such as high-fat meals that delay gastric emptying. In addition to meal coverage, pump therapy incorporates correction boluses to address hyperglycemia that is present before meals or occurs unexpectedly. Correction dosing is guided by the insulin sensitivity factor (ISF), which estimates how much one unit of insulin will lower blood glucose. ISF is commonly calculated by the formula ISF = 1700/TDD.[7] The correction bolus is frequently delivered along with the mealtime bolus, creating a combined dose that aims to address both anticipated carbohydrate exposure and existing hyperglycemia. Safe correction dosing depends on an accurate ISF and on awareness of “insulin stacking,” a phenomenon in which overlapping boluses accumulate because earlier insulin remains active. Nurses can reduce risk by ensuring that patients understand how the pump’s bolus calculator accounts for insulin already delivered, and by reinforcing that corrections should be guided by the device’s calculations rather than repeated empiric dosing that can precipitate delayed hypoglycemia.

A central feature of pump therapy is the availability of different bolus profiles designed to match diverse meal compositions and absorption kinetics. Standard bolus delivery provides a single dose delivered over a short period, appropriate for many meals with relatively predictable carbohydrate absorption. However, some meals—particularly those high in fat or protein—can cause delayed and prolonged postprandial hyperglycemia. To address this, pumps may offer dual wave, short extended, or long extended boluses. Dual wave bolus delivery involves a conventional pre-meal bolus followed by an extended bolus delivered evenly over several hours, with proportions and duration programmed by the user. Evidence comparing standard bolus delivery with dual wave bolus strategies has shown improved glycemic outcomes in patients receiving dual wave dosing, with a reduction in prolonged postprandial hyperglycemic excursions.[11] Clinically, the value of extended bolus profiles lies in their capacity to distribute insulin delivery over time, reducing early hypoglycemia and late hyperglycemia when meal absorption is prolonged. Teaching patients to use these features requires individualized coaching, because selecting the appropriate split and duration depends on meal characteristics and personal response patterns. Insulin pumps can generally be used in two principal operational modes: automated (“auto”) mode and manual mode. In auto mode, the pump typically communicates with a continuous glucose monitoring (CGM) device, and a preset algorithm adjusts basal insulin delivery in response to sensor glucose readings and trends. Examples of algorithmic systems include basal modulation platforms and more advanced control systems, sometimes described using terms such as basal IQ and control IQ.[7] Auto mode can increase safety by reducing basal insulin when glucose is falling and increasing delivery when glucose rises, thereby smoothing glycemic variability across the day and overnight. Auto mode also commonly supports temporary basal adjustments for periods of increased or decreased insulin requirement, such as illness, stress, or sustained exercise. In these circumstances, basal delivery can be modified in a structured way, often guided by the ISF and informed by glucose trends. From a nursing standpoint, auto mode education must include interpretation of device behavior—explaining why basal may increase or decrease—and emphasizing that algorithmic control does not eliminate the need for active self-management, particularly around meals. Manual mode, by contrast, relies on user- or clinician-programmed basal rates that remain fixed unless changed deliberately. Basal segments are set according to the patient's insulin needs and are adjusted over time as patterns emerge. This mode places greater responsibility on the user to recognize trends, implement temporary basal adjustments when needed, and respond to hyperglycemia or hypoglycemia using correction strategies. Manual mode remains clinically relevant in many settings, including when CGM connectivity is unavailable, when sensor issues occur, or when users prefer or require a more conventional approach. Nurses supporting patients in manual mode often emphasize pattern recognition, structured glucose review, and the importance of responding promptly to infusion-site problems that may otherwise be "masked" in systems that appear to be functioning normally [8][9][10][11].

The hybrid closed-loop system represents the first generation of automated insulin delivery, characterized by dynamic modulation of basal insulin while still requiring users to administer meal boluses.[8] This design reflects a practical compromise: while algorithms can adjust basal delivery continuously using glucose sensor inputs, accurate mealtime insulin still depends on user-entered carbohydrate estimates and appropriate bolus timing. Hybrid systems aim to reduce overnight hypoglycemia and improve time-in-range while preserving user control over prandial dosing. Looking forward, newer modalities are anticipated, including fully automated multi-hormonal closed-loop systems that may incorporate additional hormones beyond insulin to more closely replicate physiologic glucose regulation.[8] While these technologies are evolving, the clinical implication for nursing is consistent: each additional layer of automation alters the education needs, troubleshooting pathways, and monitoring priorities, but does not eliminate the requirement for safe device use and timely recognition of deteriorating glycemic control. Bolus calculators continue to evolve, and automated adjustment capabilities have been developed to improve glycemic control and reduce postprandial spikes.[9] These tools aim to integrate real-time glucose levels, trends, insulin-on-board calculations, and individualized parameters such as ICR and ISF to recommend more appropriate bolus amounts. When used correctly, bolus calculators can reduce human arithmetic errors and standardize correction logic; however, they are only as accurate as the parameters entered, reinforcing the importance of periodic clinician review and patient re-education. In clinical practice, pump therapy has been associated with improved glycemic control and a reduced need for multiple daily injections, which can improve quality of life and treatment satisfaction. Although data in very young children have not consistently demonstrated a clear superiority in glycemic outcomes, parental satisfaction is often higher with pump use, likely reflecting perceived flexibility, reduced injection burden, and enhanced monitoring tools.[10] These psychosocial dimensions are clinically relevant because satisfaction and perceived feasibility influence adherence and sustained engagement with therapy.

A key pharmacologic concept underpinning pump calculations is the duration of insulin action. Rapid-acting insulin delivered by pump does not exert its full effect instantly; rather, bolus activity declines progressively, often described as decreasing by approximately 20% to 25% each hour. Consequently, a meaningful fraction of bolus insulin remains active at the end of three to four hours, and larger boluses typically leave more insulin active at later time points.[12] Pumps incorporate this concept through "insulin action time" settings, which determine how long the device assumes a bolus remains active. The term insulin on board (IOB) describes the residual active insulin remaining after a bolus, often across the next three to five hours, as calculated by the pump using the preset action time.[12] IOB is clinically protective because it helps prevent overcorrection; if a patient delivers a correction while substantial insulin remains active, delayed hypoglycemia may occur. Nurses should emphasize that IOB is a safety feature, and that users should rely on it rather than repeatedly "chasing" hyperglycemia with additional boluses. Hypoglycemia prevention is further enhanced in sensor-augmented pumps operating in auto mode through suspension features. Threshold suspend (TS), also called low glucose suspend (LGS), interrupts insulin delivery when glucose falls below a defined threshold.[13] Evidence suggests that these features can reduce hypoglycemia rates by approximately 40% to 50% without significantly increasing HbA1c, reflecting improved safety without compromising overall glycemic control.[13] A more proactive approach is predictive low glucose suspend (PLGS), in which insulin delivery is halted approximately 30 minutes before hypoglycemia is expected based on sensor trend analysis. This predictive strategy aims to prevent the low before it occurs, reducing the need for reactive carbohydrate treatment and decreasing glycemic volatility. For nursing practice, these features shift education toward understanding alarms, interpreting suspension events, and preventing rebound hyperglycemia after prolonged insulin interruption. Patients must also learn when to verify sensor readings with finger-stick measurements, especially when symptoms and sensor values do not match, and how to safely resume insulin delivery after a suspension event. In summary, insulin delivery through pump therapy integrates continuous basal infusion with flexible bolus dosing for meals and corrections, guided by individualized parameters such as ICR and ISF and supported by safety features that account for insulin action time and insulin on board. Pumps may be used in manual mode or in increasingly automated modes that integrate CGM data to modulate basal delivery and reduce hypoglycemia risk.[7][8][9][10][11][12][13] For nurses, competence in these delivery principles is essential to provide accurate patient education, support safe troubleshooting, and promote sustained glycemic control while minimizing acute risks such as severe hypoglycemia and rapid-onset hyperglycemia due to delivery interruption.

Issues of Concern

Insulin pump therapy offers important advantages in flexibility and glycemic precision, yet it introduces a distinct set of clinical vulnerabilities that require proactive surveillance and rapid response. Because most insulin pumps deliver rapid-acting insulin analogs continuously and do not provide a long-acting "basal safety net," even short interruptions in insulin delivery can lead to clinically meaningful hyperglycemia and, in susceptible patients, progression to diabetic ketoacidosis (DKA). For nurses and other clinicians, the "issues of concern" associated with pumps should be approached as a structured risk framework: local infusion-site complications that jeopardize delivery reliability, systemic glycemic disturbances that may signal device malfunction, and rare but potentially severe adverse events that can occur during maintenance tasks such as site changes. Infusion-site complications are among the most common and most actionable problems encountered in pump users. Infection at the infusion site can present with erythema, induration, tenderness to palpation, warmth, swelling, drainage, or signs of fluid leakage around the cannula and adhesive. In addition to infection, localized inflammation may arise from mechanical irritation, allergic responses to adhesives, or repeated use of limited skin areas leading to tissue changes. Regardless of the exact cause, these clinical signs are significant because they compromise insulin absorption and increase the probability of partial or complete delivery failure. Moreover, fluid leakage at the site may represent dislodgement, cannula kinking, or loosening of the adhesive seal; any of these conditions can convert a programmed insulin dose into "intended delivery" rather than actual physiologic delivery. For this reason, visible site changes—erythema, induration, pain, or leakage—are clear indications for immediate removal and selection of a new site in a different location.[14] In nursing education, site rotation is repeatedly emphasized as a preventive strategy to reduce infection risk and preserve healthy subcutaneous tissue, thereby supporting more predictable insulin absorption over time [14].

Hyperglycemia is a critical concern in insulin pump users because it may be the earliest and most practical indicator of disrupted insulin delivery. Rapid-acting insulin analogs typically begin to work within approximately 15 minutes, peak around 60 minutes, and have a duration of action of less than five hours after injection. In a continuous subcutaneous insulin infusion system, this short duration means that the body is dependent on uninterrupted basal delivery; when delivery stops—whether due to occlusion, empty reservoir, cannula kinking, tubing disconnection, or site failure—blood glucose can rise quickly. Therefore, when a pump user develops unexplained hyperglycemia, particularly if it is persistent or accompanied by symptoms, disrupted insulin delivery must be included prominently in the differential diagnosis. Clinically, this is not simply an equipment issue; it is a metabolic emergency risk pathway, because prolonged hyperglycemia without insulin can lead to ketone production and DKA. A practical bedside principle is that the infusion site should always be inspected during the physical examination in any pump user with hyperglycemia, unexplained symptoms, or concern for insulin omission. Direct visualization can reveal redness, swelling, dampness, detachment, or signs of leakage, and palpation may identify induration or tenderness consistent with inflammation or infection. Because patient-reported "the pump is working" does not guarantee that insulin is entering subcutaneous tissue, clinicians should use a simple functional check to evaluate delivery integrity. One recommended approach is to administer an insulin bolus via the pump and recheck blood glucose afterward; if glucose remains elevated despite an appropriate bolus, it suggests that the tubing or infusion set may be compromised and requires replacement.[15] This method is clinically valuable because it tests the delivery pathway rather than relying on device menus or historical logs that may record commanded doses without confirming physiologic absorption. When the tubing or infusion set appears compromised, timely replacement is essential. However, real-world constraints may prevent immediate replacement, including lack of supplies, inadequate training, hospitalization without pump accessories, or patient impairment. In such cases, clinicians should consider reverting to multiple daily injections using long-acting and short-acting insulin to re-establish reliable insulin coverage.[15] A key practical step in this transition is calculating a long-acting insulin dose that approximates the patient's basal needs. Because basal delivery in pump therapy is programmable, the patient's basal profile can be used to estimate total basal insulin over 24 hours, and this value can inform the daily requirement of long-acting insulin. From a nursing perspective, ensuring that this transition is clear and safely executed is critical, especially during inpatient admissions or emergencies, where inconsistent delivery could prolong hyperglycemia or precipitate ketosis [15].

Diabetic ketoacidosis is an especially important issue of concern in pump therapy precisely because pump users generally do not have long-acting insulin in circulation. DKA can develop rapidly if insulin delivery is interrupted for hours, particularly in individuals with type 1 diabetes. Symptoms such as nausea, vomiting, abdominal pain, tachypnea, fatigue, and altered mental status, combined with hyperglycemia and ketonemia or ketonuria, should prompt urgent evaluation and treatment. Interestingly, studies comparing DKA incidence in patients using continuous subcutaneous insulin infusion versus multiple daily injections have reported lower rates of DKA among pump users.[16] This finding likely reflects multiple interacting factors, including enhanced engagement, improved glucose monitoring, and earlier recognition of rising glucose when pump systems are used appropriately. Nonetheless, the risk is not absent, and DKA remains a central clinical concern because when pump failure does occur, it can produce abrupt insulin deprivation. Therefore, nursing education often emphasizes sick-day rules, ketone monitoring when glucose is persistently elevated, and having an emergency backup plan that includes injection supplies and clear dosing guidance. In addition to common site and hyperglycemia-related concerns, clinicians should remain aware of rare but potentially severe events associated with pump maintenance procedures. Case reports have described episodes of hypoglycemia occurring after an infusion-site change, linked to the delivery of an unsolicited insulin bolus.[17] In these reports, a site change preceded an alarm, and a high dose of insulin appeared to have been delivered without an intentional bolus command from the user, resulting in clinically significant hypoglycemia. Although such events are uncommon, they highlight the broader safety principle that pump users should be taught to remain attentive during site changes, confirm that priming and set-change steps are performed correctly, and respond promptly to unusual alarms or unexpected glucose declines. In clinical settings, this also supports careful observation immediately after a site change in patients who are newly initiated on pump therapy, those with limited device literacy, or those with a history of severe hypoglycemia [17].

Overall, the issues of concern in insulin pump therapy cluster around the reliability of subcutaneous access and the metabolic consequences of disrupted delivery. Local signs of infection, inflammation, or leakage warrant immediate site removal and relocation.[14] Unexplained hyperglycemia should prompt direct inspection of the infusion site and functional verification of insulin delivery, with infusion set replacement when indicated.[15] Because pump therapy lacks long-acting insulin coverage, clinicians must maintain a heightened awareness of DKA risk and ensure patients have clear contingency plans, even as population data suggest that DKA incidence may be lower among pump users in routine practice.[16] Finally, rare reports of unsolicited bolus delivery during site changes underscore the importance of patient education, alarm interpretation, and early monitoring after pump maintenance.[17] In nursing practice, these concerns translate into structured patient teaching, vigilant assessment, and rapid escalation when glycemic instability suggests pump malfunction, thereby maximizing the benefits of pump therapy while minimizing preventable harm.

Clinical Significance

Insulin pump therapy, clinically defined as continuous subcutaneous insulin infusion (CSII), has become a cornerstone technology for intensifying insulin management, particularly in individuals with type 1 diabetes and selected patients with insulin-requiring type 2 diabetes. Its clinical significance is grounded in evidence that CSII can improve glycemic control, reduce hypoglycemia risk in certain populations, and enhance patient-reported satisfaction by offering greater flexibility and precision than traditional multiple daily injection (MDI) regimens. From a nursing and interprofessional care perspective, the importance of pump therapy extends beyond glycemic metrics alone: it influences day-to-day self-management demands, modifies risk profiles for acute complications such as severe hypoglycemia and diabetic ketoacidosis, and increasingly reshapes long-term strategies aimed at reducing microvascular and macrovascular sequelae through improved stability of glucose exposure. Early randomized evidence comparing CSII to injection-based regimens helped establish the clinical value of pump therapy. In a foundational randomized study, DeVries compared CSII to MDI using NPH and regular insulin and demonstrated a reduction in hemoglobin A1c of 0.84% at 16 weeks.[18] This magnitude of improvement is clinically meaningful because A1c reductions of this size are associated with lower risk of microvascular complications in long-term epidemiologic and interventional literature. While the specific insulin formulations used in earlier comparative trials differ from current practice—given the subsequent availability of rapid-acting analogs and advanced basal insulins—the signal remains important: continuous infusion can produce superior glycemic outcomes when compared with regimens constrained by the pharmacokinetic limitations of older insulins and less flexible delivery schedules [19].

Subsequent multicenter evaluations reinforced and nuanced these findings. The 5-Nations trial, conducted across 11 European centers, reported a hemoglobin A1c decrease of 0.22% when CSII was compared with MDI regimens using NPH.[19][20] Although the A1c reduction was smaller than that observed in the earlier randomized study, the trial also reported a lower incidence of hypoglycemic events and higher user-perceived satisfaction among pump users.[19][20] This combination of findings is central to the clinical significance of pump therapy: improved outcomes are not limited to a single biomarker, and benefits may include a safer glycemic profile and better acceptability to patients. Satisfaction is not merely a “soft” endpoint; it correlates with adherence, sustained engagement, and willingness to perform the ongoing behaviors required for safe insulin intensification, such as frequent monitoring, accurate carbohydrate estimation, and timely response to hyperglycemia alarms or infusion-site concerns. Hypoglycemia remains one of the most consequential barriers to tight glycemic control, and pump therapy has long been scrutinized for its relationship to hypoglycemic risk. Because CSII can lower A1c, clinicians historically worried that improved glycemic control might come at the cost of increased hypoglycemia. However, evidence suggests that severe hypoglycemia outcomes may be reduced rather than increased in pump users. Studies comparing CSII with MDI have shown that event rates of severe hypoglycemia and hypoglycemic coma were significantly lower with CSII than with injection therapy.[16] Clinically, this can be explained by several pump-related advantages: the capacity to tailor basal rates by time of day, to suspend or reduce basal delivery during or after activity, and to apply more precise correction logic that accounts for insulin on board. In sensor-augmented systems, automated basal reductions and suspend features further strengthen the safety profile by preventing or attenuating impending hypoglycemia, thereby supporting lower A1c without proportionally increasing severe events [16].

Beyond average glucose exposure, pump therapy is increasingly valued for its impact on glycemic variability. Numerous studies have reported reduced blood glucose variability among insulin pump users.[21] This reduction is clinically important because variability is associated with symptomatic burden—patients often experience fewer abrupt swings between hyperglycemia and hypoglycemia—and may influence long-term complication risk. Preliminary investigations have suggested that glycemic variability could represent a pathophysiologic mechanism contributing to diabetic complications, including nephropathy, retinopathy, coronary artery disease, and cognitive decline, although further research is needed to establish causation rather than association.[22] Even in the absence of definitive causal proof, the potential link strengthens the rationale for strategies that reduce glycemic excursions, because variability may reflect repeated oxidative stress and endothelial injury. In this context, pump therapy is clinically significant not only for lowering A1c but also for potentially reshaping the "quality" of glycemic control by smoothing peaks and troughs that are difficult to address with fixed injection schedules. The clinical indications for insulin pump therapy reflect both disease type and treatment complexity. Pump therapy is widely considered appropriate for all patients with type 1 diabetes, given the absolute requirement for insulin and the advantages of programmable basal delivery and flexible bolusing.[23] Within type 1 diabetes, pump therapy is particularly valuable for individuals who experience frequent hypoglycemia or who have unpredictable glycemic patterns that complicate MDI management. Pump therapy is also indicated for selected patients with type 2 diabetes who fail to meet glycemic targets despite intensive MDI regimens and substantial lifestyle modifications, because continuous infusion can simplify high-frequency dosing and provide greater titration precision.[24] Certain physiologic and lifestyle circumstances further strengthen pump candidacy. Individuals with gastroparesis may benefit from extended bolus features that match delayed gastric emptying and reduce late postprandial hyperglycemia.[25] Pregnancy is another important indication, as tighter glucose targets are often required to reduce maternal and fetal complications, and the ability to adjust basal and bolus doses with precision can help meet these targets under close clinical supervision.[26] Patients with variable schedules, including shift workers, may also benefit from programmable basal profiles and temporary basal adjustments that better align insulin delivery with changing sleep–wake cycles and meal timing.[25] Pediatric patients, who may require very small insulin doses and experience rapid changes in insulin sensitivity due to growth and activity, can be particularly well suited to pump therapy because pumps can deliver fine increments that may be difficult to replicate accurately with injections.[27]

While pump therapy can be broadly beneficial, outcomes are optimized when patients are well matched to the demands of the technology. Ideal candidates are typically willing to wear the pump—often continuously—and, when using sensor-augmented systems, to wear a glucose sensor as well. Motivation and sustained engagement with pump education are critical, because safe pump use requires understanding basal versus bolus insulin, carbohydrate counting, infusion-set maintenance, and troubleshooting steps when hyperglycemia suggests delivery failure. Adequate vision and manual ability support safe operation of device interfaces, which may include touchscreen navigation, button sequences, or menu-driven programming. Competence in carbohydrate counting is particularly important because bolus accuracy hinges on estimation of intake, and misunderstandings can lead to recurrent excursions. Patients must also be able to calculate or verify bolus doses using the device's bolus calculator, interpret insulin-on-board recommendations, and respond appropriately to alarms. Importantly, "ideal candidate" characteristics should not be used to exclude patients unfairly; rather, they highlight educational and support needs. When barriers exist—such as limited health literacy or anxiety regarding technology—structured training, simplified teaching tools, and ongoing follow-up can enable safe adoption. Finally, the clinical significance of pump therapy must be interpreted in the context of rapid technological evolution. Insulin pump systems are increasingly integrated with continuous glucose monitoring and algorithmic control, offering hybrid closed-loop and progressively automated features that can reduce workload while improving time-in-range. This rapid advancement creates an implementation challenge for healthcare professionals who must remain current with device capabilities, safety alerts, and updated best practices. Nevertheless, a solid conceptual understanding of pump insulin delivery—basal programming, bolus calculation, insulin action time, infusion-site reliability, and hypoglycemia prevention—equips clinicians to prevent common complications and support effective therapy even as device models evolve. In this way, insulin pump therapy represents not only a technological upgrade but also a clinically significant shift toward individualized, data-driven insulin management that can improve glycemic outcomes, reduce severe hypoglycemia, and enhance quality of life when supported by comprehensive education and coordinated care [25][26][27].

Nursing, Allied Health, and Interprofessional Team Interventions

Safe insulin pump therapy within clinical environments depends on coordinated, interprofessional interventions that prioritize continuity, role clarity, and rapid escalation when glycemic stability is threatened. Because pump users rely on continuous delivery of rapid-acting insulin, lapses in communication during admission, transfer, peri-procedural care, or discharge can quickly translate into missed insulin, inappropriate duplicative insulin administration, or delayed recognition of infusion failure. For this reason, the interprofessional team must maintain clear, consistent communication during every transition of care so that all clinicians involved understand that the patient is using an insulin pump and can align orders, monitoring plans, and contingency strategies accordingly. This includes documenting pump use prominently in the medical record, verifying the device type and insulin concentration, and confirming whether the patient is also using a continuous glucose monitoring (CGM) system, since these factors influence monitoring workflows and risk assessment. A central intervention principle is that pump programming changes should be made only by individuals with appropriate competence. In routine practice, the patient—if cognitively intact and trained—or a certified pump specialist is typically the most qualified to adjust settings such as mealtime boluses, correction boluses, temporary basal rates, or time-segmented basal profiles. This approach reduces the likelihood of programming errors by staff who may not be familiar with device-specific menus and safety features. It also supports patient autonomy and preserves the individualized settings that the outpatient diabetes team has refined over time. Nevertheless, when persistent hyperglycemia occurs, when infusion-site integrity is questionable, or when the device is removed for imaging or procedures, these developments must be communicated rapidly to the responsible physician and diabetes care team to prevent progression to ketone formation or DKA. Early escalation is particularly important when hyperglycemia does not respond to an appropriately delivered pump bolus, which may suggest infusion set failure and necessitate immediate troubleshooting or transition to injectable insulin.

In many hospitals, systems exist that allow patients to continue using their insulin pumps during inpatient admission.[28] This practice can maintain stable glycemic patterns and reduce the disruptive effects of abrupt regimen changes, but it is appropriate only when specific safety prerequisites are met. The patient must be able to consent to continued pump use and must be willing and capable of independently managing the device, including bolus dosing, infusion set changes, troubleshooting alarms, and responding to hyperglycemia or hypoglycemia. This requirement reflects a practical reality: many inpatient teams do not have formal training in pump management, and assuming staff will "run the pump" can create unsafe ambiguity. Accordingly, the inpatient plan should explicitly define who is responsible for pump actions and what circumstances trigger a change in management. Importantly, in all settings, healthcare professionals retain the authority to suspend pump therapy and transition the patient to a conventional insulin regimen when doing so is necessary for patient safety. This may occur during anesthesia, when the patient's mental status is altered, during critical illness, or whenever the patient is not fully awake or able to manage the pump reliably. In these circumstances, structured transition protocols—typically involving basal insulin replacement and scheduled prandial/correction dosing—help prevent both insulin omission and unintended overlap. Allied health professionals strengthen these interventions through targeted roles. Diabetes educators and pump specialists provide bedside reinforcement of pump skills, confirm that the patient can navigate device functions, and support staff by clarifying device-specific steps. Pharmacists contribute by verifying insulin type and concentration, screening for medication interactions that may affect glycemic control (such as corticosteroids), and assisting in safe conversion to injection-based regimens when needed. Dietitians support accurate carbohydrate planning and meal timing, which is essential for appropriate bolus dosing. Together, these interventions create a safety net that preserves the benefits of pump therapy while ensuring rapid response when conditions change.[28]

Nursing, Allied Health, and Interprofessional Team Monitoring

Monitoring for inpatient insulin pump users must be systematic, documentation-driven, and responsive to the unique safety profile of continuous subcutaneous insulin infusion. Because basal insulin delivery occurs continuously and bolus dosing is frequently patient-initiated, the nursing team plays a central role in ensuring that glucose trends are tracked reliably and that deviations are acted upon early. A core expectation is maintaining a clear log of blood glucose values and relevant pump parameters, including basal rate settings and any temporary basal changes. This documentation supports clinical accountability and enables timely identification of patterns that may require intervention, such as persistent hyperglycemia suggesting infusion failure, recurrent nocturnal hypoglycemia indicating excessive basal delivery, or repeated postprandial spikes that may reflect inaccurate carbohydrate estimation. In many settings, monitoring relies on partnership with the patient. When a patient uses CGM, nursing documentation often incorporates patient-reported glucose values and trend data, because the device may provide frequent readings that can guide earlier detection of deterioration.[29] However, institutional practices vary, and some hospitals require confirmatory point-of-care capillary testing for treatment decisions, particularly in situations where CGM accuracy may be reduced—such as during rapid glucose changes, poor peripheral perfusion, or when certain medications interfere with sensor performance. Nurses therefore must understand the local policy governing how CGM data can be used and when fingerstick confirmation is required. Regardless of the data source, the monitoring objective remains the same: detect abnormal trends early and escalate promptly to prevent complications. A second monitoring priority involves verifying ongoing eligibility for independent pump management. Because the safety model for inpatient pump use often assumes that the patient is the primary operator, nurses must routinely assess whether the patient remains alert, oriented, and capable of performing essential pump tasks. Any decline in mental status, severe nausea or vomiting, procedural sedation, or new critical illness should trigger re-evaluation of whether pump continuation remains safe and whether a transition to a staff-managed conventional insulin regimen is indicated. This assessment is not punitive; it reflects the time-sensitive risk of insulin interruption or mis-dosing when patients are unable to self-manage [28][29][30].

Documentation requirements commonly include formal evidence that the patient consented to continued pump use and demonstrated ability to manage the device independently.[30] Hospitals may have specific paperwork or electronic attestation forms, and the details can vary across institutions. In addition, nursing notes frequently capture the presence of infusion sites, observed skin integrity, and any alarms or device issues reported by the patient. Monitoring also includes recognizing and documenting infusion-site complications—such as erythema, induration, tenderness, or leakage—because these findings can compromise insulin absorption and are often the earliest signs of impending delivery failure. When hyperglycemia is persistent, nurses should ensure that troubleshooting steps are initiated quickly, including site inspection, verification of reservoir status, and communication with the medical team if glucose remains elevated despite corrective measures. Allied health professionals complement nursing monitoring by providing specialized oversight. Diabetes educators can validate patient competency and reinforce troubleshooting pathways. Pharmacists can monitor medications that raise glucose levels and support safe insulin conversions if pump suspension is necessary. Dietitians can align carbohydrate intake with bolus planning, reducing avoidable postprandial excursions. In combination, structured nursing documentation, patient-partnered glucose reporting, competency reassessment, and institution-specific consent processes create a monitoring framework that supports safe inpatient continuation of insulin pump therapy and reduces the risk of preventable dysglycemic events.[29][30]

Conclusion:

Insulin pump therapy has transformed diabetes management by enabling continuous, programmable insulin delivery that closely mimics physiologic patterns. Evidence demonstrates that CSII can lower HbA1c, reduce glycemic variability, and decrease severe hypoglycemia compared to traditional injection regimens. These benefits extend beyond biochemical metrics, improving quality of life and treatment satisfaction for patients across diverse populations, including pediatric, pregnant, and high-risk individuals. Despite its advantages, pump therapy introduces unique vulnerabilities. Because it relies exclusively on rapid-acting insulin, even brief interruptions in delivery can precipitate hyperglycemia and diabetic ketoacidosis. Infusion-site complications, device malfunctions, and user errors remain critical concerns. Consequently, successful implementation depends on structured patient education, competency verification, and proactive monitoring. Interprofessional collaboration—encompassing nurses, diabetes educators, pharmacists, and dietitians—is essential to ensure safe inpatient continuation, prevent insulin omission, and manage transitions effectively. As technology advances toward hybrid and fully automated closed-loop systems, nursing practice must adapt to evolving device capabilities while maintaining foundational principles of insulin delivery, troubleshooting, and patient engagement. Ultimately, insulin pump therapy exemplifies the intersection of technology and individualized care, offering substantial clinical benefits when supported by comprehensive education and vigilant oversight.

References:

1. Bratke H, Margeirsdottir HD, Assmus J, Njølstad PR, Skrivarhaug T. Does Current Diabetes Technology Improve Metabolic Control? A Cross-Sectional Study on the Use of Insulin Pumps and Continuous Glucose Monitoring Devices in a Nationwide Pediatric Population. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2021 Sep:12(9):2571-2583. doi: 10.1007/s13300-021-01127-6.
2. Marks BE, Wolfsdorf JI, Waldman G, Stafford DE, Garvey KC. Pediatric Endocrinology Trainees' Education and Knowledge About Insulin Pumps and Continuous Glucose Monitors. Diabetes technology & therapeutics. 2019 Mar:21(3):105-109. doi: 10.1089/dia.2018.0331.
3. Sebastian SA, Co EL, Mehendale M, Hameed M. Insulin analogs in the treatment of type II diabetes and future perspectives. Disease-a-month : DM. 2023 Mar:69(3):101417. doi: 10.1016/j.disamonth.2022.101417.
4. Tremblay ES. Persistent Socioeconomic Disparities in Insulin Pump Uptake Despite Universal Health Coverage-Nonmonetary Drivers in Insulin Pump Use. JAMA network open. 2022 May 2:5(5):e2210471. doi: 10.1001/jamanetworkopen.2022.10471.
5. Lane WS, Weinrib SL, Lawrence MJ, Lane BC, Jarrett RT. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2022 Feb:28(2):165-172. doi: 10.1016/j.eprac.2021.11.001.
6. Deberles E, Morello R, Hardouin J, Amadou C, Benhamou PY, Prévost G, Schaepelynck P, Chaillous L, Joubert M, Reznik Y. The switch from rapid-acting to concentrated regular insulin improves glucose control in type 2 diabetes patients on pump therapy: A cohort survey. Diabetes & metabolism. 2022 May:48(3):101300. doi: 10.1016/j.diabet.2021.101300.
7. Kamecke U, Waldenmaier D, Haug C, Ziegler R, Freckmann G. Establishing Methods to Determine Clinically Relevant Bolus and Basal Rate Delivery Accuracy of Insulin Pumps. Journal of diabetes science and technology. 2019 Jan:13(1):60-67. doi: 10.1177/1932296818788349.
8. Weaver KW, Hirsch IB. The Hybrid Closed-Loop System: Evolution and Practical Applications. Diabetes technology & therapeutics. 2018 Jun:20(S2):S216-S223. doi: 10.1089/dia.2018.0091.
9. Herrero P, Pesl P, Bondia J, Reddy M, Oliver N, Georgiou P, Toumazou C. Method for automatic adjustment of an insulin bolus calculator: in silico robustness evaluation under intra-day variability. Computer methods and programs in biomedicine. 2015 Apr:119(1):1-8. doi: 10.1016/j.cmpb.2015.02.003.
10. Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, Waugh N. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health technology assessment (Winchester, England). 2010 Feb:14(11):iii-iv, xi-xvi, 1-181. doi: 10.3310/hta14110.
11. Metwally M, Cheung TO, Smith R, Bell KJ. Insulin pump dosing strategies for meals varying in fat, protein or glycaemic index or grazing-style meals in type 1 diabetes: A systematic review. Diabetes research and clinical practice. 2021 Feb:172():108516. doi: 10.1016/j.diabres.2020.108516.
12. Rosales N, De Battista H, Vehí J, Garelli F. Open-loop glucose control: Automatic IOB-based super-bolus feature for commercial insulin pumps. Computer methods and programs in biomedicine. 2018 Jun:159():145-158. doi: 10.1016/j.cmpb.2018.03.007.
13. Grassi B, Onetto MT, Zapata Y, Jofré P, Echeverría G. Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile. Diabetes & metabolic syndrome. 2021 May-Jun:15(3):695-701. doi: 10.1016/j.dsx.2021.03.017.
14. Berg AK, Nørgaard K, Thyssen JP, Zachariae C, Hommel E, Rytter K, Svensson J. Skin Problems Associated with Insulin Pumps and Sensors in Adults with Type 1 Diabetes: A Cross-Sectional Study. Diabetes technology & therapeutics. 2018 Jul:20(7):475-482. doi: 10.1089/dia.2018.0088.

15. Dogan ADA, Jørgensen UL, Gjessing HJ. Diabetic Ketoacidosis Among Patients Treated With Continuous Subcutaneous Insulin Infusion. Journal of diabetes science and technology. 2017 May:11(3):631-632. doi: 10.1177/1932296816668375.
16. Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, Boettcher C, Kapellen T, Rosenbauer J, Holl RW. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA. 2017 Oct 10:318(14):1358-1366. doi: 10.1001/jama.2017.13994.
17. Faulds ER, Wyne KL, Buschur EO, McDaniel J, Dungan K. Insulin Pump Malfunction During Hospitalization: Two Case Reports. Diabetes technology & therapeutics. 2016 Jun:18(6):399-403. doi: 10.1089/dia.2015.0434.
18. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ, Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes care. 2002 Nov:25(11):2074-80
19. Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB, 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabetic medicine : a journal of the British Diabetic Association. 2006 Feb:23(2):141-7
20. McAuley SA, Vogrin S, Lee MH, Paldus B, Trawley S, de Bock MI, Abraham MB, Bach LA, Burt MG, Cohen ND, Colman PG, Davis EA, Hendrieckx C, Holmes-Walker DJ, Jenkins AJ, Kaye J, Keech AC, Kumareswaran K, MacIsaac RJ, McCallum RW, Sims CM, Speight J, Stranks SN, Sundararajan V, Ward GM, Jones TW, O'Neal DN, Australian JDRF Closed-Loop Research Group. Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes technology & therapeutics. 2021 Jun:23(6):460-466. doi: 10.1089/dia.2020.0589
21. Petrelli F, Cangelosi G, Scuri S, Pantanetti P, Lavorgna F, Faldetta F, De Carolis C, Rocchi R, Debernardi G, Florescu A, Nittari G, Sagaro GG, Garda G, Nguyen CTT, Grappasonni I. Diabetes and technology: A pilot study on the management of patients with insulin pumps during the COVID-19 pandemic. Diabetes research and clinical practice. 2020 Nov:169():108481. doi: 10.1016/j.diabres.2020.108481.
22. Zhang ZY, Miao LF, Qian LL, Wang N, Qi MM, Zhang YM, Dang SP, Wu Y, Wang RX. Molecular Mechanisms of Glucose Fluctuations on Diabetic Complications. Frontiers in endocrinology. 2019:10():640. doi: 10.3389/fendo.2019.00640.
23. Zhang L, Leng X, Tian F, Xiao D, Xuan J, Yang H, Liu J, Chen Z. Cost-effectiveness analysis of continuous subcutaneous insulin infusion versus multiple daily insulin for treatment of children with type 1 diabetes. Postgraduate medicine. 2022 Aug:134(6):627-634. doi: 10.1080/00325481.2022.2088938.
24. Li Q, Wang L, Xiao L, Wang Z, Wang F, Yu X, Yan S, Wang Y. Effect of intensive insulin therapy on first-phase insulin secretion in newly diagnosed type 2 diabetic patients with a family history of the disease. Experimental and therapeutic medicine. 2015 Feb:9(2):612-618
25. Morros-González E, Gómez AM, Henao Carrillo DC, Ursida V, Serrano S, Rondón Sepúlveda MA, Muñoz Velandia OM. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia. Diabetes & metabolic syndrome. 2021 May-Jun:15(3):649-653. doi: 10.1016/j.dsx.2021.02.029.
26. O'Malley G, Ozaslan B, Levy CJ, Castorino K, Desjardins D, Levister C, McCrady-Spitzer S, Church MM, Kaur RJ, Reid C, Kremers WK, Doyle FJ, Trinidad MC, Rosenn B, Pinsker JE, Kudva YC, Dassau E. Longitudinal Observation of Insulin Use and Glucose Sensor Metrics in Pregnant Women with Type 1 Diabetes Using Continuous Glucose Monitors and Insulin Pumps: The LOIS-P Study. Diabetes technology & therapeutics. 2021 Dec:23(12):807-817. doi: 10.1089/dia.2021.0112.

27. Alemzadeh R, Palma-Sisto P, Holzum M, Parton E, Kicher J. Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus. Diabetes technology & therapeutics. 2007 Aug:9(4):339-47
28. Umpierrez GE, Klonoff DC. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes care. 2018 Aug:41(8):1579-1589. doi: 10.2337/dci18-0002.
29. Vettoretti M, Facchinetti A. Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review. Biomedical engineering online. 2019 Mar 29:18(1):37. doi: 10.1186/s12938-019-0658-x.
30. Yeh T, Yeung M, Mendelsohn Curanaj FA. Managing Patients with Insulin Pumps and Continuous Glucose Monitors in the Hospital: to Wear or Not to Wear. Current diabetes reports. 2021 Jan 15:21(2):7. doi: 10.1007/s11892-021-01375-7.

.

.